<DOC>
	<DOCNO>NCT00696293</DOCNO>
	<brief_summary>The following primary hypothesis test : 1 . During Step 1 : Major Depressive Disorder ( MDD ) Chronic Low Back Pain ( CLBP ) &lt; 40 % initial 60 subject treat duloxetine ( DUL ) + Clinical Management ( CM ) first 8 week respond ( response define Montgomery Asberg Depression Rating Scale ( MADRS ) score &lt; /=9 least 30 % improvement back pain measure 20-point numeric rating scale . 2 . During Step 2 : More DUL+Problem Solving Therapy Depression Pain ( PST-DP ) DUL+CM treat subject achieve response second 8 week , define MADRS score &lt; /=9 least 30 % improvement back pain measure 2-point numeric rating scale . 3 . Improvement depression score correlate improvement CLBP score . The exploratory hypothesis test : During Step 2 : Compared subject treat DUL+CM , subject treat DUL+PST-DP improved outcome : 1 ) disability , 2 ) sleep , 2 ) functioning/quality life , 3 ) caregiver burden/depression , 5 ) analgesic use .</brief_summary>
	<brief_title>Duloxetine Treatment Major Depression Chronic Low Back Pain For Older Adults</brief_title>
	<detailed_description>This two-part study . Step 1 8-week long open-label trial duloxetine ( DUL ) + clinical management ( CM ) , titrate 90 mg/day , old adult comorbid major depressive disorder ( MDD ) chronic low back pain ( CLBP ) . At week 8 , subject respond , dose duloxetine increase 120 mg/day . Duloxetine increase continue 120 mg/day ( high tolerate dose ) randomize study group ( step 2 ) assure medication parity . Step two start week 9 include subject whose MDD and/or CLBP meet criterion response Step 1 . At week 9 subject randomize receive treatment either : 1 ) DUL 120 mg/day ( high tolerate dose ) + Problem Solving Depression Pain ( PST-DP ) 2 ) DUL 120 mg/day ( high tolerate dose ) + CM . Step 2 delivered course 8-10 session . NOTE ADDED 1/5/16 : THIS WAS TREATMENT DEVELOPMENT WORK CONDUCTED AS PART OF A CAREER DEVELOPMENT AWARD . ONLY THE FIRST OPEN-LABEL PART OF THE STUDY WAS COMPLETED , AND THESE RESULTS HAVE BEEN PUBLISHED AND WILL BE REPORTED HERE ON CLINICALTRIALS.GOV</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Age &gt; /= 60 Current episode MDD per SCID DSMIV criterion Must score &gt; /= 16 CESD assessment Serum sodium &gt; /=130 mEq/ml CLBP least moderate severity day &gt; /= 3 month MADRS score &gt; /= 15 Sufficiently medically stable able participate depression treatment protocol Willingness ability speak English Access translator limit . It would unsafe treat old adult speak English antidepressant able effectively communicate progress side effect . We provide 24/7 oncall service subject enrol study . The oncall clinician physicians bilingual , problem arose , may impossible effectively interpret manage emergent situation . Finally , many assessment use study selfreports . At present time , ability translate instrument languages . If subject read understand English , would interfere ability complete selfreport assessment Willingness discontinue antidepressant anxiolytic , except lorazepam 2 mg/day Mini Mental State Exam &gt; 20 Willingness provide inform consent Corrected visual ability enable read newspaper headline hear capacity adequate respond raise conversational voice . Meet DSMIV criterion dementia History bipolar , schizophrenia , schizoaffective , psychotic disorder Alcohol drug abuse ( include abuse prescription medication ) within past 6 month History treatment nonadherence protocol run MidLife LateLife Centers Acute pain superimpose chronic pain . For example , subject report `` red flag '' suggest herniated disk , vertebral fracture , infection , cauda equina syndrome , medical emergency exclude Wheelchair bound History document nonresponse duloxetine Concurrent use thioridazine Active suicidal ideation plan Uncontrolled narrow angle glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>